FDA OKs low-dose colchicine for broad CV indication.
| Autor: | Sue Hughes |
|---|---|
| Předmět: | |
| Zdroj: | Family Practice News; Jun2023, p1-3, 3p |
| Abstrakt: | The article focuses on the U.S. Food & Drug Administration's (FDA) approval of low-dose colchicine (Lodoco) as the first specific anti-inflammatory drug for adult patients. It discusses about reducing the risk of cardiovascular events in adult patients with established atherosclerotic disease or multiple cardiovascular risk factors; and the drug, which targets residual inflammation, can be used alone or in combination with cholesterol-lowering medications. |
| Databáze: | Complementary Index |
| Externí odkaz: |
|